Skip Nav Destination
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial
Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma
ctDNA MRD after CAR-T
Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers
Issue Archive
November 11 2025
Table of Contents
INSIDE BLOOD ADVANCES
SYSTEMATIC REVIEW
Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis
Hassan Kawtharany,Muayad Azzam,Aseel Alkhader,Marisol Betensky,Qais Hamarsha,Hadi K. Abou Zeid,Razan Mansour,Carine Tabak,Payal Patel,Sarah L. Baghdadi,Rachel S. Bercovitz,Rukhmi Bhat,Tina Biss,Brian R. Branchford,Leonardo R. Brandão,Anthony K. C. Chan,E. Vincent S. Faustino,Julie Jaffray,Sophie Jones,Bryce A. Kerlin,Nicole Kucine,Riten Kumar,Christoph Male,Marie-Claude Pelland-Marcotte,Leslie Raffini,Chittalsinh M. Raulji,Sarah E. Sartain,Clifford M. Takemoto,Cristina Tarango,C. Heleen van Ommen,Maria C. Velez,Sara K. Vesely,John Wiernikowski,Suzan Williams,Hope P. Wilson,Gary Woods,Ayesha Zia,Paul Monagle,Reem A. Mustafa
CLINICAL TRIALS AND OBSERVATIONS
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Clinical Trials & Observations
Kitsada Wudhikarn,Megan M. Herr,Min Chen,Michael J. Martens,John H. Baird,Lohith Gowda,Hemalatha G. Rangarajan,Muhammad Bilal Abid,Mohamed A. Kharfan-Dabaja,Kirsten M. Williams,Siddhartha Ganguly,Jo-Anne H. Young,Akshay Sharma,Giancarlo Fatobene,Tania Jain,Christopher G. Kanakry,Dipenkumar Modi,Natalie S. Grover,Baheyeldin Salem,Marjorie Vieira Batista,Paschalis Vergidis,Dwight E. Yin,Amer M. Beitinjaneh,Amar H. Kelkar,Taiga Nishihori,Jennifer Holter Chakrabarty,Usama Gergis,Melody Smith,Zeinab El Boghdadly,Christopher E. Dandoy,Hemant S. Murthy,Anna R. Huppler,Miguel-Angel Perales,Roy F. Chemaly,Joshua A. Hill,Marcie Riches,Jeffery J. Auletta
Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort
Clinical Trials & Observations
Henning Nilius,Ekaterina Sinitsa,Jan-Dirk Studt,Dimitrios A. Tsakiris,Andreas Greinacher,Adriana Mendez,Adrian Schmidt,Walter A. Wuillemin,Bernhard Gerber,Prakash Vishnu,Lukas Graf,Johanna A. Kremer Hovinga,Tamam Bakchoul,Michael Nagler
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial
Clinical Trials & Observations
Raphael Steiner,Liana Nikolaenko,Ranjit Nair,Venkatraman Seshan,Swetha Kambhampati Thiruvengadam,Niloufer Khan,Jeremy S. Abramson,Steven Horwitz,Matthew Matasar,Colette Owens,Ildefonso Ismael Rodriguez Rivera,David J. Straus,Timothy S. Pardee,Sanjeev Luther,Sabrina Saboukoulou,Win Su Thet,Shreya Vemuri,Ariela Noy
Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy
Clinical Trials & Observations
Oluwatobi Odetola,Shuo Ma,Jane Winter,Barbara Pro,Ishan Roy,Ping Xie,Bin Zhang,Qing Chen,George P. Koulogeorgas,Xinlei Mi,Ruohui Chen,Yangruijue Ma,Xiaodan Tang,Robert Bayer,Robert Eisner,Valerie Nelson,Habib Shaikh,Dean Tsarwhas,Faisal Saghir,Parameswaran Venugopal,Leo I. Gordon,Reem Karmali
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Clinical Trials & Observations
Kirk Cahill,James Godfrey,Chadi Nabhan,Justin Kline,Peter A. Riedell,Kenneth S. Cohen,Sunil Narula,Theodore G. Karrison,Jessica Robertson,Reem Karmali,Parameswaran Venugopal,Seo-Hyun Kim,Aaron P. Rapoport,Seung Tae Lee,Jennie Law,Paul A. S. Fishkin,Iris Isufi,Mario Velasco,Lynne Kaminer,Sonali M. Smith
HEALTH SERVICES AND OUTCOMES
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Zachary D. Epstein-Peterson,Anath C. Lionel,Ashlee Joseph,Esther Drill,Suheil Albert Atallah-Yunes,Taylor R. Brooks,Elise A. Chong,Emeline R. Chong,Jamie Dela Cruz,Matthew J. Frank,Andrew Ip,Madiha Iqbal,Caron A. Jacobson,Manali K. Kamdar,Reem Karmali,Ofrat Beyar-Katz,Kami J. Maddocks,Matthew J. Matasar,Daniel McLoughlin,Reid W. Merryman,Javier L. Munoz,Rohini Navalekar,Joanna Rhodes,Peter A. Riedell,Christine E. Ryan,Gilles Salles,Craig S. Sauter,Yazeed Sawalha,Samanvaya Sharma,Roni Shouval,Navika Shukla,Dylan Therwhanger,Herman van Besien,Ben Varon,Yucai Wang,Samuel Yamshon,Andrew D. Zelenetz,Maria Lia Palomba,Preetesh Jain,Anita Kumar
IMMUNOBIOLOGY AND IMMUNOTHERAPY
HLA-E[pHLA-G] complex–specific monoclonal antibody enhancing NK activity in multiple myeloma
Muhammad Abu Ahmad,Olga Radinsky,Bar Kaufman,Kamran Waidha,Eman Gharra,Sharon Dim,Dinesh Babu Manikandan,Noa Ofir,Dirk Jäger,Marten Meyer,Moshe Elkabets,Kerry S. Campbell,Miri Zektser,Roi Gazit,Ory Rouvio,Frank Momburg,Angel Porgador
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Clinical Trials & Observations
Hemalatha G. Rangarajan,Prakash Satwani,Megan M. Herr,Min Chen,Michael J. Martens,Kitsada Wudhikarn,Samuel John,Vanessa A. Fabrizio,Emily M. Hsieh,Amar H. Kelkar,Erin Doherty,David I. Marks,Olle Ringden,Brian Friend,Matthew S. Kelly,Nosha Farhadfar,Tim Prestidge,Nasheed M. Hossain,Hongtao Liu,Shahrukh Hashmi,Dipenkumar Modi,Lena E. Winestone,Zeinab El Boghdadly,Hemant S. Murthy,Miguel-Angel Perales,Roy F. Chemaly,Christopher E. Dandoy,Joshua A. Hill,Anna Huppler,Marcie Riches,Jeffery J. Auletta
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
Xavier Deschênes-Simard,Maria Bromberg,Sean M. Devlin,Mithat Gonen,Ofrat Beyar-Katz,Andrew Ip,Ronit Marcus,Abraham Avigdor,Annamaria Ballweg,Emma Rabinovich,Mohammad Alhomoud,Alfredo Rivas Delgado,Magdalena Corona De Lapuerta,Alejandro Luna De Abia,Maria Lia Palomba,Gunjan L. Shah,Richard Lin,Alexander P. Boardman,Lorenzo Falchi,Jennifer Lue,Gilles Salles,Miguel-Angel Perales,Roni Shouval,Parastoo B. Dahi,Michael Scordo
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL
Janneke W. de Boer,Kylie Keijzer,Suzanne van Dorp,Pim G. N. J. Mutsaers,Anne G. H. Niezink,Jaap A. van Doesum,Yasmina I. M. Serroukh,Louise W. Muntendam,Astrid E. Pulles,Esther J. Kret,Aniko Sijs-Szabo,Jesse Oomen,Astrid M. P. Demandt,Wendy B. C. Stevens,Maria T. Kuipers,Elise R. A. Pennings,Anne M. Spanjaart,Marie José Kersten,Margot Jak,Lisanne V. van Dijk,Marjolein W. M. van der Poel,Joost S. P. Vermaat,Tom van Meerten,on behalf of the Dutch CAR-T Tumorboard Consortium
LYMPHOID NEOPLASIA
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study
Alberto Fresa,Idanna Innocenti,Annamaria Tomasso,Candida Vitale,Alessandro Sanna,Anna Maria Frustaci,Andrea Visentin,Azzurra Romeo,Paolo Sportoletti,Annamaria Giordano,Francesca Perutelli,Roberta Murru,Francesca Romana Mauro,Antonio Mosca,Francesca Morelli,Roberta Laureana,Andrea Galitzia,Ilaria Angeletti,Esmeralda Conte,Riccardo Moia,Giovanni D’Arena,Raffaella Pasquale,Francesco Autore,Jacopo Olivieri,Luca Stirparo,Giulia Benintende,Francesco Angotzi,Florenzia Vuono,Andrea Corbingi,Maria Ilaria Del Principe,Diana Giannarelli,Alessandra Tedeschi,Marta Coscia,Eugenio Sangiorgi,Dimitar G. Efremov,Luca Laurenti
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Brett Collinge,Laura K. Hilton,Jasper Wong,Waleed Alduaij,Susana Ben-Neriah,Graham W. Slack,Pedro Farinha,Merrill Boyle,Barbara Meissner,James R. Cook,German Ott,Andreas Rosenwald,Elias Campo,Catalina Amador,Timothy C. Greiner,Philipp W. Raess,Joo Y. Song,Giorgio Inghirami,Sarah L. Ondrejka,Elaine S. Jaffe,Dennis D. Weisenburger,Wing C. Chan,Harald Holte,Klaus Beiske,Kai Fu,Jan Delabie,Stefania Pittaluga,Javeed Iqbal,George Wright,Kerry J. Savage,Andrew J. Mungall,Louis M. Staudt,Christian Steidl,Andrew L. Feldman,Ryan D. Morin,Lisa M. Rimsza,David W. Scott
Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study
Eugenio Galli,Roberta Di Blasi,Alice Di Rocco,Caterina Cristinelli,Ilaria Pansini,Côme Bommier,Alessandro Corrente,Ilenia De Bernardis,Marcello Viscovo,Stefan Hohaus,Anna Modoni,Federica Sorà,Patrizia Chiusolo,Maurizio Martelli,Simona Sica,Catherine Thieblemont
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma
Clinical Trials & Observations
Nira Krasnow,Katie Maurer,Catherine Song,Justin Rhoades,Kan Xiong,Andjela Crnjac,Timothy Blewett,Lily Gao,Heather Jacene,Reid Merryman,Satyen H. Gohil,Caitlyn Duffy,Liliana I. Guerrero,Jamie Dela Cruz,Mikaela McDonough,Jacquelyn O. Wolff,Robert Redd,Mike Mattie,Brodie Miles,G. Mike Makrigiorgos,Donna S. Neuberg,Scott J. Rodig,Philippe Armand,Caron Jacobson,Viktor A. Adalsteinsson,Catherine J. Wu
ctDNA MRD after CAR-T
Clinical Trials & Observations
MYELOID NEOPLASIA
Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia
Jessica Liegel,Dina Stroopinsky,Giulia Cheloni,Dimitra Karagkouni,Myrna Nahas,Yuling Ma,Daniela Torres,Isabella Saldarriaga,Shuoshuo Wang,Antonella Arruda de Amaral,Athanasios Ploumakis,John Clohessy,Joseph Abirached,Lina Bisharat,Paula Fraenkel,Ozlem Yildirim,Hélène Bonnevaux,Stephane Guerif,Katie Rallis,Georges Chedid,Donald Kufe,Ioannis S. Vlachos,David Avigan,Jacalyn Rosenblatt
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase
Warren Fiskus,Lucia Masarova,Christopher P. Mill,Christine E. Birdwell,Kaberi Das,Hanxi Hou,John A. Davis,Antrix Jain,Anna Malovannaya,Taghi Manshouri,Andrew Dunbar,Surbhi Sharma,Tapan M. Kadia,Courtney D. DiNardo,Prithviraj Bose,Naveen Pemmaraju,Sanam Loghavi,Xiaoping Su,Raajit K. Rampal,Marie Törngren,Kapil N. Bhalla
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
A disrupted adenosinergic axis facilitates platelet activation in APS: exploring a novel therapeutic target
Somanathapura K. NaveenKumar,Thalia G. Newman,Bruna Mazetto Fonseca,Srilakshmi Yalavarthi,Mariane C. Flores Nascimento,Kaitlyn Sabb,Katarina Kmetova,Emily Chong,Kavya Sugur,Caroline H. Ranger,Megan P. Tompkins,Cyrus Sarosh,Jacqueline A. Madison,Ajay Tambralli,Jordan K. Schaefer,Michael Holinstat,Yu Zuo,Jason S. Knight
TRANSPLANTATION
Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers
Clinical Trials & Observations
Teresa Caballero-Velázquez,Javier Delgado Serrano,Lucía López-Corral,Christelle Ferra-Coll,Clara Beatriz García-Calderón,David Valcárcel,Irene García-Cadenas,Estefanía Pérez López,María-José Jiménez Lorenzo,Francisco Manuel Martín-Domínguez,María de los Reyes Jiménez-León,Guillermo Orti,Virginia Escamilla Gómez,Cristina Blázquez-Goñi,Almudena Cabero Martínez,Henry Andrade Ruiz,Estefanía Menéndez-Pedregal,Fermín Sánchez-Guijo,José Antonio Pérez Simón
RESEARCH LETTERS
Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS
Jón Þórir Óskarsson,Sigrun Thorsteinsdottir,Sæmundur Rögnvaldsson,Andri Ólafsson,Gunnhildur Viðarsdóttir,Elfa Rún Guðmundsdóttir,Elias Eythorsson,Ásbjörn Jónsson,Brynjar Viðarsson,Páll T. Önundarson,Bjarni A. Agnarsson,Margrét Sigurðardóttir,Ingunn Þorsteinsdóttir,Ísleifur Ólafsson,Stephen J. Harding,Brian GM Durie,Thorvardur Jon Love,Sigurdur Y. Kristinsson
-
Cover Image
Cover Image
Image depicting molecular docking of venetoclax (pink structure) and conjugate A1 (blue structure) bound to Bcl-2 (Protein Data Bank [PDB] code: 6O0K) and Bcl-xL (PDB code: 4QNQ). Venetoclax and A1 made a critical similar hydrogen bond between the azaindole moiety and Bcl-2 D103, and the introduced dihydroartemisinin fragment of A1 formed a novel hydrogen bond with Bcl-2 R106 (upper Figure). A1 and venetoclax bound to Bcl-xL with a similar binding mode at the P2 pocket Bcl-xL, but a markedly different mode at the P4 pocket, which led to a significant reduction in potency against Bcl-xL (lower Figure). See the article by Zhang et al.
Advertisement intended for health care professionals
Advertisement intended for health care professionals





















After the fog has lifted: infections with CD19 CAR-T therapy
Clinical Trials & Observations